KRAS and colorectal cancer: In the Sidra-LUMC AC-ICAM cohort, CMS1 (38 cases) containing MSI colorectal cancers presented lower rates of mutations in APC, KRAS, and TP53 than other groups and higher rates of mutations in BRAF and epigenetic modifiers (Figure 2).